Search
AxoGen Inc
AXGNAdd to Watchlist
44.020USD
-2.170-4.70%
Close 07/01, 16:00（ET）Quotes delayed by 15 min
2.08BMarket Cap
LossP/E TTM
More Details of AxoGen Inc Company
Axogen, Inc. is focused on the science, development, and commercialization of technologies for peripheral nerve regeneration and repair. It offers repair solutions for surgeons and healthcare providers. Its portfolio of products includes Avance Nerve Graft, Axoguard Nerve Connector, Axoguard Nerve Protector, Axoguard HA+ Nerve Protector, Axoguard Nerve Cap, and Avive+ Soft Tissue Matrix. Avance Nerve Graft is a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves. The Axoguard Nerve Connector is a porcine (pig) submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves. Axoguard Nerve Protector is a porcine submucosa ECM product used to wrap and protect damaged peripheral nerves and reinforce the nerve reconstruction while preventing soft tissue attachments. Axoguard HA+ Nerve Protector consists of a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating.
AxoGen Inc Info
Ticker SymbolAXGN
Company nameAxoGen Inc
IPO dateDec 17, 1986
CEODale (Michael Donald)
Number of employees451
Security typeOrdinary Share
Fiscal year-endDec 17
Address13631 Progress Blvd.
CityALACHUA
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code32615
Phone13864626817
Websitehttps://www.axogeninc.com/
Ticker SymbolAXGN
IPO dateDec 17, 1986
CEODale (Michael Donald)
Company Executives of AxoGen Inc
Name
Name/Position
Position
Shareholding
Change
Ms. Lindsey Hartley
Ms. Lindsey Hartley
Chief Financial Officer
Chief Financial Officer
65.15K
+6.77%
Mr. Jens Schroeder Kemp
Mr. Jens Schroeder Kemp
Chief Marketing Officer
Chief Marketing Officer
64.95K
-6.16%
Mr. Paul G. Thomas
Mr. Paul G. Thomas
Independent Chairman of the Board
Independent Chairman of the Board
28.93K
+65.23%
Mr. Erick Wayne Devinney
Mr. Erick Wayne Devinney
Chief Innovation Officer
Chief Innovation Officer
--
--
Ms. Amy A. Mcbride-Wendell
Ms. Amy A. Mcbride-Wendell
Lead Independent Director
Lead Independent Director
--
--
Mr. Alan M. Levine
Mr. Alan M. Levine
Independent Director
Independent Director
--
--
Mr. John H. Johnson
Mr. John H. Johnson
Independent Director
Independent Director
--
--
Mr. William P. (Bill) Burke
Mr. William P. (Bill) Burke
Independent Director
Independent Director
--
--
Dr. Joseph (Adrian) Tyndall, M.D.
Dr. Joseph (Adrian) Tyndall, M.D.
Independent Director
Independent Director
--
--
Mr. Marc A. Began
Mr. Marc A. Began
Executive Vice President, Chief Compliance Officer, General Counsel
Executive Vice President, Chief Compliance Officer, General Counsel
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Ms. Lindsey Hartley
Ms. Lindsey Hartley
Chief Financial Officer
Chief Financial Officer
65.15K
+6.77%
Mr. Jens Schroeder Kemp
Mr. Jens Schroeder Kemp
Chief Marketing Officer
Chief Marketing Officer
64.95K
-6.16%
Mr. Paul G. Thomas
Mr. Paul G. Thomas
Independent Chairman of the Board
Independent Chairman of the Board
28.93K
+65.23%
Mr. Erick Wayne Devinney
Mr. Erick Wayne Devinney
Chief Innovation Officer
Chief Innovation Officer
--
--
Ms. Amy A. Mcbride-Wendell
Ms. Amy A. Mcbride-Wendell
Lead Independent Director
Lead Independent Director
--
--
Mr. Alan M. Levine
Mr. Alan M. Levine
Independent Director
Independent Director
--
--
FAQs
Who are the top five shareholders of AxoGen Inc?
The top five shareholders of AxoGen Inc are: Ms. Lindsey Hartley
How many institutions hold shares of AxoGen Inc (AXGN)?
As of 2026Q1, 399 institutions hold shares of AxoGen Inc, with a combined market value of approximately 48.71M, accounting for 91.60% of the total shares. Compared to 2025Q4, institutional shareholding has increased by 3148593.00.